期刊文献+

神经鞘磷脂合成酶SMS1和SMS2在人乳腺癌组织中的表达及与病理的相关性 被引量:2

Expression of sphingomyelin synthetase SMS1 and SMS2 in human breast cancer tissue and its correlation with pathology
在线阅读 下载PDF
导出
摘要 目的探究神经鞘磷脂合成酶SMS1和SMS2在人乳腺癌组织中的表达及与病理的相关性。方法收集2015年1月至2018年6月乳腺癌组织及对应癌旁组织标本各50例,检测SMS1、SMS2表达水平,并分析其与临床病理参数的关系。结果乳腺癌组织中SMS1、SMS2阳性表达率均高于癌旁组织(P<0.05);多因素Logistic回归分析结果显示,分化程度、淋巴结转移是SMS1阳性表达的危险因素(P<0.05);临床分期、分化程度、淋巴结转移是SMS2阳性表达的危险因素(P<0.05)。结论 SMS1、SMS2在乳腺癌组织中高表达,可能参与乳腺癌的病情进展,且与分化程度及淋巴结转移相关。 Objective To investigate the expression of sphingomyelin synthetase SMS1 and SMS2 in human breast cancer tissue and its correlation with pathology. Methods From January 2015 to June 2018, 50 samples of breast cancer tissues and corresponding adjacent tissues were collected. The expression of SMS1 and SMS2 were analyzed, and the relationship between them with clinicopathological parameters were analyzed. Results The positive expression rates of SMS1 and SMS2 in the breast cancer tissues were higher than those in the adjacent tissues(P <0.05). The multivariate Logistic regression analysis showed that differentiation and lymph node metastasis were the risk factors of positive expression of SMS1(P<0.05);the clinical stage, differentiation and lymph node metastasis were the risk factors of positive expression of SMS2(P<0.05). Conclusion SMS1 and SMS2 are highly expressed in the breast cancer tissues. It may be involved in the progress of breast cancer, and related to the degree of differentiation and lymph node metastasis.
作者 潘云青 PAN Yun-qing(Pathology Department,Nanyang Second General Hospital,Nanyang 473000,China)
出处 《临床医学研究与实践》 2019年第32期124-125,共2页 Clinical Research and Practice
关键词 神经鞘磷脂合成酶 乳腺癌 淋巴结转移 sphingomyelin synthase breast cancer lymph node metastasis
  • 相关文献

参考文献6

二级参考文献108

  • 1李庆芳,王立生.鞘氨醇激酶调节细胞凋亡的研究进展[J].军事医学科学院院刊,2005,29(1):84-86. 被引量:9
  • 2杨栋,杨丽霞.神经酰胺在细胞凋亡中的作用[J].国际病理科学与临床杂志,2006,26(2):166-168. 被引量:5
  • 3Huitema K, van den Dikkenberg J, Brouwers JF, et af. Identification of a family of animal sphingon lyelin synthases[J]. EMBO J ,2004,23(1) :33 44.
  • 4Mitsutake S, Igarashi Y. Sphingolipids in lipid microdornains and obesity[J]. Vitam Horm, 2013,91 : 271 - 284.
  • 5Martin ML, Liebisch G, Lehneis S, et al. Sustained activation of sphingomye/in synthase by 2 hydroxyoieic acid induces sphingolipidosis in tumor cells[J]. J Lipid Res,2013,54(5):1457 1465.
  • 6Brandstaetter H,Kendrick-Jones J,Buss F, et al. Myolc regulates lipid raft recycling to control cell spreading, migration and Salmonella invasion[J]. J Cell Sci, 2012, ]25(Pt 8) : 1991 - 2003.
  • 7JiangXC, Paultre F, Pearson TA, et al. Plasmasphingomyelin level as a risk factor for coronary artery disease[J]. Arterioscler Th rornb Vasc B iol , 2000,20 (12) : 2614- 2618.
  • 8Zhao YR,Dong JP,,Li Y,et al. Sphingomyelin synthase 2 over-expression induces expression of aortic inflammatory biomarkers and decreases circulating EPCs in ApoE KO mice[J]. Life Sci,2012,90(21 - 22) :867 - 873.
  • 9Yan NL, Ding TB, Dong JB, et al. Sphingomyelin synthasc overexpression increases cholesterol accumulation and decreases cholesterol secretion in liver cells[J]. Lipids Health Dis, 20 l 1, I 0 : 46.
  • 10Ding TB, Li Z, Hailemariam T,et al. SMS overexpression and knockdown: impact on cellular sphingomyelin and diacylglyeerol metabolism,and cell apoptosis [J]. J Lipid Res,2008,49(2) :376 - 385.

共引文献18

同被引文献21

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部